Vycor Medical

Vycor Medical is a commercial-stage company with two complementary divisions targeting significant neurological care markets. Its flagship product, the ViewSite Brain Access System (VBAS), is a minimally invasive, FDA-cleared surgical device for brain lesion access, supported by over 50 clinical studies. The NovaVision division commercializes the only FDA-cleared therapy for vision restoration after stroke (VRT) and a complementary compensation therapy (NeuroEyeCoach), addressing a large, underserved patient population. The company boasts a strong intellectual property portfolio with 48 patents and is led by a management team with significant ownership.

Minimally invasive surgical access devices (VBAS) and computer-based, non-invasive neurovisual rehabilitation software (NovaVision VRT & NeuroEyeCoach).

In neurosurgical access, VBAS competes with traditional retractors and other minimally invasive systems from larger players. Its differentiation is its specific cylindrical design and clinical data. In vision rehab, NovaVision's VRT is the only FDA-cleared restorative therapy, giving it a unique position versus generic compensatory training or investigational approaches.